NCT04086823View on ClinicalTrials.gov

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

September 16, 2020

Study Completion Date

September 16, 2020

Conditions

Submental Fat

Interventions

DRUG

RZL-012

Subcutaneous injection to the submental fat area

DRUG

Placebo

Trial Locations (1)

60611

DeNova Research, Chicago

All Listed Sponsors

lead

Raziel Therapeutics Ltd.

INDUSTRY

NCT04086823 - A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers. | Biotech Hunter | Biotech Hunter